Premium
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program
Author(s) -
Houghton Peter J.,
Morton Christopher L.,
Kolb E. Anders,
Gorlick Richard,
Lock Richard,
Carol Hernan,
Reynolds C. Patrick,
Maris John M.,
Keir Stephen T.,
Billups Catherine A.,
Smith Malcolm A.
Publication year - 2008
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21296
Subject(s) - in vivo , rhabdomyosarcoma , medicine , sarcoma , pi3k/akt/mtor pathway , in vitro , pharmacology , osteosarcoma , cancer research , sirolimus , transplantation , pathology , biology , apoptosis , biochemistry , microbiology and biotechnology
Background Rapamycin is a highly specific inhibitor of mTOR, a serine/threonine kinase that controls cap‐dependent translation. Here we report the activity of rapamycin against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). Procedures Rapamycin was tested against the in vitro panel at concentrations from 0.01 to 100 nM and was tested against the in vivo tumor panels by i.p. administration daily × 5 for 6 consecutive weeks at a dose of 5 mg/kg. Results Rapamycin variably inhibited growth of the cell lines in the PPTP in vitro panel, with maximal inhibition values ranging from 19% to 85% (median 49%) and a median EC 50 of 0.7 nM. Ten of 23 cell lines achieved at least 50% growth inhibition. Against the in vivo panels, rapamycin induced significant differences in EFS distribution in 27 of 36 solid tumor xenografts and in 5 of 8 ALL xenografts. Using the time to event activity measure, rapamycin had intermediate or high activity against 14 of 31 evaluable solid tumor xenografts and 5 of 8 ALL xenografts. Objective responses were observed in several panels, including: rhabdoid tumor (1PR), rhabdomyosarcoma (2PR), and osteosarcoma (1 maintained CR). Two T‐cell ALL xenografts had objective responses (1PR, 1 maintained CR). Conclusions Rapamycin demonstrated broad antitumor activity against the PPTP's in vivo tumor panels, with particularly noteworthy activity for selected sarcoma and ALL xenografts. Future work will evaluate the molecular characteristics of responding models and the activity of combinations of rapamycin with other anticancer agents. Pediatr Blood Cancer 2008;50:799–805. © 2007 Wiley‐Liss, Inc.